Cargando…

The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease

Hippocampal changes are associated with increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer's disease (AD). These associations are often observed only in the later stages of decline. This study examined if hippocampal grading, a method measuring local morpho...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Cassandra, Dadar, Mahsa, Shafiee, Neda, Collins, D. Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171554/
https://www.ncbi.nlm.nih.gov/pubmed/36939138
http://dx.doi.org/10.1002/hbm.26269
_version_ 1785039443589070848
author Morrison, Cassandra
Dadar, Mahsa
Shafiee, Neda
Collins, D. Louis
author_facet Morrison, Cassandra
Dadar, Mahsa
Shafiee, Neda
Collins, D. Louis
author_sort Morrison, Cassandra
collection PubMed
description Hippocampal changes are associated with increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer's disease (AD). These associations are often observed only in the later stages of decline. This study examined if hippocampal grading, a method measuring local morphological similarity of the hippocampus to cognitively normal controls (NCs) and AD participants, is associated with cognition in NCs, subjective cognitive decline (SCD), early (eMCI), late (lMCI), and AD. A total of 1620 Alzheimer's Disease Neuroimaging Initiative participants were examined (495 NC, 262 eMCI, 545 lMCI, and 318 AD) because they had baseline MRIs and Alzheimer's disease Assessment Scale (ADAS‐13) and Clinical Dementia Rating—Sum of Boxes (CDR‐SB) scores. In a sub‐analysis, NCs with episodic memory scores (as measured by Rey Auditory Verbal Learning Test, RAVLT) were divided into those with subjective cognitive decline (SCD+; 103) and those without (SCD−; 390). Linear regressions evaluated the influence of hippocampal grading on cognition in preclinical and prodromal AD. Lower global cognition, as measured by increased ADAS‐13, was associated with hippocampal grading: NC (p < .001), eMCI (p < .05), lMCI (p < .05), and AD (p = .01). Lower global cognition as measured increased CDR‐SB was associated with hippocampal grading in lMCI (p < .05) and AD (p < .001). Lower RAVLT performance was associated with hippocampal grading in SCD− (p < .05) and SCD+ (p < .05). These findings suggest that hippocampal grading is associated with global cognition in NC, eMCI, lMCI, and AD. Early changes in episodic memory during pre‐clinical AD are associated with changes in hippocampal grading. Hippocampal grading may be sensitive to progressive changes early in the disease course.
format Online
Article
Text
id pubmed-10171554
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-101715542023-05-11 The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease Morrison, Cassandra Dadar, Mahsa Shafiee, Neda Collins, D. Louis Hum Brain Mapp Research Articles Hippocampal changes are associated with increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer's disease (AD). These associations are often observed only in the later stages of decline. This study examined if hippocampal grading, a method measuring local morphological similarity of the hippocampus to cognitively normal controls (NCs) and AD participants, is associated with cognition in NCs, subjective cognitive decline (SCD), early (eMCI), late (lMCI), and AD. A total of 1620 Alzheimer's Disease Neuroimaging Initiative participants were examined (495 NC, 262 eMCI, 545 lMCI, and 318 AD) because they had baseline MRIs and Alzheimer's disease Assessment Scale (ADAS‐13) and Clinical Dementia Rating—Sum of Boxes (CDR‐SB) scores. In a sub‐analysis, NCs with episodic memory scores (as measured by Rey Auditory Verbal Learning Test, RAVLT) were divided into those with subjective cognitive decline (SCD+; 103) and those without (SCD−; 390). Linear regressions evaluated the influence of hippocampal grading on cognition in preclinical and prodromal AD. Lower global cognition, as measured by increased ADAS‐13, was associated with hippocampal grading: NC (p < .001), eMCI (p < .05), lMCI (p < .05), and AD (p = .01). Lower global cognition as measured increased CDR‐SB was associated with hippocampal grading in lMCI (p < .05) and AD (p < .001). Lower RAVLT performance was associated with hippocampal grading in SCD− (p < .05) and SCD+ (p < .05). These findings suggest that hippocampal grading is associated with global cognition in NC, eMCI, lMCI, and AD. Early changes in episodic memory during pre‐clinical AD are associated with changes in hippocampal grading. Hippocampal grading may be sensitive to progressive changes early in the disease course. John Wiley & Sons, Inc. 2023-03-20 /pmc/articles/PMC10171554/ /pubmed/36939138 http://dx.doi.org/10.1002/hbm.26269 Text en © 2023 The Authors. Human Brain Mapping published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Morrison, Cassandra
Dadar, Mahsa
Shafiee, Neda
Collins, D. Louis
The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
title The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
title_full The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
title_fullStr The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
title_full_unstemmed The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
title_short The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
title_sort use of hippocampal grading as a biomarker for preclinical and prodromal alzheimer's disease
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171554/
https://www.ncbi.nlm.nih.gov/pubmed/36939138
http://dx.doi.org/10.1002/hbm.26269
work_keys_str_mv AT morrisoncassandra theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT dadarmahsa theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT shafieeneda theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT collinsdlouis theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT morrisoncassandra useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT dadarmahsa useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT shafieeneda useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT collinsdlouis useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease
AT useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease